Literature DB >> 11229833

Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarine discontinuation. A prospective, randomized, open study.

C G Fondevila1, S H Grosso, M T Santarelli, M D Pinto.   

Abstract

We performed a prospective, randomized, open study in 109 outpatients under chronic anticoagulation with acenocoumarine, presenting with International Normalized Ratios (INRs) > or = 6.0 and no or minor bleeding. All the patients withheld one dose of acenocoumarine; in addition, a treated group also received 1 mg oral vitamin K1. We aimed at a post-intervention INR < 6.0, with a target zone of 2.0-4.0. The INRs were lowered from a mean of 8.1 +/- 1.7 to 4.9 +/- 2.5 in the controls (P = 0.0000) and from 8.4 +/- 2.4 to 3.3 +/- 3 in the treated patients (P = 0.0000). There were no differences in the percentage of patients with post-intervention INRs < 6.0 or within the therapeutic zone. One-third of the treated patients and only 2% of the controls reached INRs < 2.0 (P = 0.0003). Oral vitamin K1 offered no advantage to the simple discontinuation of one dose of acenocoumarine. A substantial number of treated patients were consequently exposed to under-anticoagulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11229833     DOI: 10.1097/00001721-200101000-00002

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  6 in total

Review 1.  Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.

Authors:  Andrea Lee; Mark Crowther
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

Review 2.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis.

Authors:  Rasha Khatib; Maja Ludwikowska; Daniel M Witt; Jack Ansell; Nathan P Clark; Anne Holbrook; Wojtek Wiercioch; Holger Schünemann; Robby Nieuwlaat
Journal:  Blood Adv       Date:  2019-03-12

4.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.

Authors:  Daniel M Witt; Robby Nieuwlaat; Nathan P Clark; Jack Ansell; Anne Holbrook; Jane Skov; Nadine Shehab; Juliet Mock; Tarra Myers; Francesco Dentali; Mark A Crowther; Arnav Agarwal; Meha Bhatt; Rasha Khatib; John J Riva; Yuan Zhang; Gordon Guyatt
Journal:  Blood Adv       Date:  2018-11-27

Review 5.  Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient.

Authors:  Michael Makris; Joost J van Veen; Rhona Maclean
Journal:  J Thromb Thrombolysis       Date:  2010-02       Impact factor: 2.300

Review 6.  Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review.

Authors:  Sarah E Wilson; Henry G Watson; Mark A Crowther
Journal:  CMAJ       Date:  2004-03-02       Impact factor: 8.262

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.